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ABSTRACT
Background. For esophageal adenocarcinoma treated
with neoadjuvant chemotherapy, postoperative staging
classifications initially developed for non-pretreated tumors
may not accurately predict prognosis. We tested whether a
multifactorial TNM-based histopathologic prognostic score
(PRSC), which additionally applies to tumor regression,
may improve estimation of prognosis compared with the
current Union for International Cancer Control/American
Joint Committee on Cancer (UICC) staging system.
Patients and Methods. We evaluated esophageal adeno-
carcinoma specimens following cis/oxaliplatin-based therapy
from two separate centers (center 1: n = 280; and center 2:
n = 80). For the PRSC, each factor was assigned a value
from 1 to 2 (ypT0-2 = 1 point; ypT3-4 = 2 points;
ypN0 = 1 point; ypN1-3 = 2 points; B50 % residual
tumor/tumor bed = 1 point; [50 % residual tumor/tumor
bed = 2 points). The three-tiered PRSC was based on
the sum value of these factors (group A: 3; group B: 4–5;
group C: 6) and was correlated with patients’ overall survival
(OS).
Results. The PRSC groups showed significant differences
with respect to OS (p \ 0.0001; hazard ratio [HR] 2.2
[95 % CI 1.7–2.8]), which could also be demonstrated in
both cohorts separately (center 1 p \ 0.0001; HR 2.48
[95 % CI 1.8–3.3] and center 2 p = 0.015; HR 1.7 [95 %
CI 1.1–2.6]). Moreover, the PRSC showed a more accurate
prognostic discrimination than the current UICC staging
system (p \ 0.0001; HR 1.15 [95 % CI 1.1–1.2]), and
assessment of two goodness-of-fit criteria (Akaike Infor-
mation Criterion and Schwarz Bayesian Information
Criterion) clearly supported the superiority of PRSC over
the UICC staging.
Conclusion. The proposed PRSC clearly identifies three
subgroups with different outcomes and may be more
helpful for guiding further therapeutic decisions than the
UICC staging system.
Preoperative chemo- or radiochemotherapy (CTX or
RCTX) followed by resection has been shown to provide
survival benefit for patients with locally advanced esoph-
ageal adenocarcinoma compared with surgery alone1–4.
Accurate postoperative staging is important for correct
estimation of prognosis and for further therapeutic deci-
sions. The new Union for International Cancer Control/
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American Joint Committee on Cancer (UICC/AJCC) TNM
classification (7th edition; TNM7) shows a better prog-
nostic stratification for primary resected esophageal cancer
compared with the 6th edition (TNM6)5,6. However, the
accuracy of this current classification in neoadjuvant-trea-
ted esophageal adenocarcinoma is unknown7. For gastric
cancer, we have recently demonstrated that a multifactorial
histopathologic prognostic score (PRSC) that included the
factors ypT category, ypN category and degree of histo-
pathological tumor regression8 could accurately classify
three groups of patients with different outcomes after
neoadjuvant CTX followed by surgery9. In this study we
investigated whether a similar, but tumor site-specific,
PRSC can be applied in esophageal adenocarcinoma.
Moreover, we aimed to determine whether this PRSC may
provide a more accurate estimation of the prognosis com-
pared with the current UICC/AJCC staging system.
MATERIALS AND METHODS
Patients
Three hundred and sixty resection specimens from
patients with histologically confirmed, locally advanced
esophageal adenocarcinoma [staged cT3/4 N(any) cM0]
from two independent academic centers were investigated.
There were 14 females (3.9 %) and 346 males (96.1 %),
with a median age of 57 years (range 25–80 years). The
median survival, which was calculated from the day of
surgery onward, was 37 months (95 % confidence interval
[CI] 28–45 months). There was no difference between both
centers regarding age, gender distribution, or survival.
Patients had undergone neoadjuvant cis/oxaliplatin/5FU-
based CTX (mainly cisplatin/5FU/leucovorin regimen)
followed by esophagectomy without adjuvant treatment
between 1995 and 2010 at the Department of Surgery at the
Technische Universita¨t Mu¨nchen (n = 280) or the Uni-
versity of Heidelberg (n = 80)10. Eighteen patients in the
Munich cohort and 13 patients in the Heidelberg cohort
(total 31 patients) had been treated with additional radio-
therapy. The protocols for neoadjuvant treatment had been
approved by the Institutional Review Boards. Table 1
summarizes tumor and patient characteristics, including
treatment.
Histopathologic Evaluation
The resection specimens had been prospectively exam-
ined according to a standardized protocol8,11 which
included the investigation of the entire macroscopically
identifiable tumor or the area with scarring indicating the
previous site of the tumor (the tumor bed). Tumor regres-
sion grading (TRG; according to Becker et al.8) was based
on an estimation of the percentage of residual tumor tissue
in relation to the macroscopically identifiable tumor bed at
the primary site of the tumor, consisting of three grades:
grade 1—complete or subtotal regression (\10 % residual
TABLE 1 Tumor and patient characteristics of the two patient
cohorts
Factor Center 1
(Munich)
Center 2
(Heidelberg)
Total
ypT category
ypT0 21 17 38
ypT1 39 4 43
ypT2 51 13 64
ypT3 165 42 207
ypT4 4 4 8
ypN category
ypN0 121 38 159
ypN1 52 20 72
ypN2 57 7 64
ypN3 50 15 65
Distant metastases
Absent 235 64 299
Present 45 16 61
Tumor grading
G1 2 0 2
G2 94 29 123
G3 149 49 198
G4 10 0 10
R category
R0 231 80 311
R1 43 0 43
R2 6 0 6
Tumor regression grade (Becker)
TRG1a 21 17 38
TRG1b 59 8 64
TRG2 63 11 77
TRG3 137 44 181
Neoadjuvant treatment
PLF 167 9 176
PLF-Taxol 65 1 66
OLF 22 3 25
EOX 2 48 50
RCTX 18 13 31
Other platin-based
CTX
6 6 12
Total 280 80 360
PLF cisplatin/5FU/leucovorine, OLF oxaliplatin/5FU/leucovorin,
EOX epirubicin, oxaliplatin, capecitabin, RCTX radiochemotherapy
(C45 Gy cis/oxaliplatin based)
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tumor per tumor bed; grade 1a is complete regression and
grade 1b is subtotal regression); grade 2—partial tumor
regression (10–50 % residual tumor per tumor bed); and
grade 3—minimal or no tumor regression ([50 % residual
tumor per tumor bed). All cases were reclassified according
to the current UICC/AJCC TNM system12.
Prognostic Score
Analogous to our previous study in gastric cancer,9 the
factors TRG, ypT and ypN category were first each
assigned a point value according to the respective prog-
nostic impact (see electronic supplementary material
[ESM] file 1): TRG (TRG factor): grade 1 and grade 2 (i.e.
\50 % residual tumor) = 1 point; grade 3 (i.e. C50 %
residual tumor) = 2 points; UICC/AJCC ypT category
(ypT factor): ypT0–ypT2 = 1 point; ypT3–ypT4 = 2
points; UICC/AJCC ypN category (ypN factor): ypN0 = 1
point; ypN1–ypN3 = 2 points. The raw PRSC consisted of
the sum of the values of these single factors with a possible
range from 3 to 6 points, and was further subclassified into
three groups of patients according to the survival curves of
each sum score: Group A with a sum of 3 points, group B
with a sum of 4–5 points, and group C with a sum of 6
points (Fig. 1; see also ESM file 2).
Statistical Analysis
IBM SPSS statistics 21 software (SPSS Inc., Chicago,
IL, USA) and SAS V9.2 (The SAS Institute, Cary, NC,
USA)were used for statistics. Descriptive associations
between single variables were evaluated by Chi squared
tests and Fisher’s exact tests. Univariate analysis of sur-
vival was performed using the Kaplan–Meier method to
estimate survival probabilities in patient subgroups, and the
log-rank test was used for statistical comparisons. Cox
proportional hazard models were performed to investigate
multivariate relationships of covariates with survival.
Ninety-five percent CIs were used to determine the effect
of each variable on outcome. All tests were two-sided, and
the significance level was set at 5 %. In order to estimate
the goodness-of-fit of each PRGS model in comparison to
UICC/AJCC staging, the Akaike Information Criterion
(AIC) and Schwarz Bayesian Information Criterion (SBC)
were used. Both methods adjust the -2 log likelihood
statistics for the number of parameters in the model and
number of observations used. Lower values of AIC and
SBC indicate superior model fit with the ‘best’ model
showing the lowest values for both.
RESULTS
Pathologic Findings
The histopathologic findings of the tumors are given in
Table 2. The survival curves, demonstrating the prognostic
relevance of the value assignment of each single factor, are
provided in the ESM supplemental file 1. No significant
survival difference was found between the two patient
groups of the two different surgical centers with respect to
the respective factor subclassifications.
Group A
Group B
Group C
Censored
PRSC
P < 0.001
1.0
0.8
0.6
0.4
0.2
Months after surgery
b
Estimated probability
of survival
a
600 12 24 36 48
FIG. 1 Histopathologic prognostic
score (PRSC): a construction of PRSC;
b PRSC and 5-year overall survival
TABLE 2 PRSC and UICC/AJCC stages
UICC/AJCC stage Total
0a I II III IV
PRSC
A 28 47 0 0 5 80
B 0 21 69 51 26 167
C 0 0 0 83 30 113
Total 28 68 69 134 61 360
UICC/AJCC Union for International Cancer Control/American Joint
Committee on Cancer, PRSC histopathologic prognostic score
a No UICC/AJCC stage for ypT0yN0
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Regarding single TNM parameters and tumor regres-
sion, a significant association was noted between tumor
regression and the UICC ypT and ypN categories (each
p \ 0.001) in the total patient cohort of both centers.
However, of the 66 cases with a subtotal tumor regression,
20 (30.3 %) had an infiltration of the adventitial tissue and
beyond, and were therefore classified as ypT3 (19 cases,
Fig. 1) and ypT4 (one case). Five of the 38 patients
(13.2 %) with complete regression of the primary tumor
had lymph node metastases, and five (13.2 %) had distant
metastases.
According to the UICC/AJCC anatomic staging system,
20 patients (5.6 %) had UICC/AJCC tumor stage IA, 48
patients (13.3 %) had stage IB, 52 patients (14.4 %) had
stage IIA, 17 patients (4.7 %) had stage IIB, including
three patients with complete tumor regression at the pri-
mary site of the tumor but with ypN1. Of 51 patients
(14.2 %) with stage IIIA tumors, one patient had complete
tumor regression at the primary site and but ypN2. Thirty-
seven patients (10.3 %) were stage IIIB, 46 patients
(12.8 %) were stage IIIC and 61 patients (16.9 %) had
stage IV tumors, among them five patients with complete
tumor regression. Twenty-eight patients (7.8 %) had no
residual tumor at the primary site and no lymph node
metastases. No difference was found between the two
centers regarding the distribution of UICC/AJCC stages.
Prognostic Score
The PRSC classified three groups of patients: group A
with 80 patients (22.2 %), group B with 167 patients
(46.4 %), and group C with 113 patients (31.4 %). In the
Munich cohort, group A comprised 60 patients (21.4 %),
group B comprised 137 patients (48.9 %), and group C
comprised 83 patients (29.6 %). In the Heidelberg cohort
20 patients (25 %) were classified into group A, and 30
patients (37.5 %) each into group B and group C. No sig-
nificant difference was noted between both centers
regarding the distribution of prognostic groups.
Comparison with Prognosis
The PRSC showed a highly significant association with
prognosis in the whole case collection (p \ 0.0001),
Munich collective (p \ 0.0001), and the Heidelberg col-
lective (p = 0.015). Regarding the whole case collection,
the PRSC discriminated significantly between the three
prognostic groups. In group A, the median overall survival
(OS) was not reached. Group B patients had a median OS
of 45 months (95 % CI 31–58 months), and group C
patients had a median OS of 20 months (95 % CI 14–
26 months). The overall difference was highly significant
(p \ 0.001, log rank analysis), as were the differences
between groups A and B (p = 0.029), groups A and C
(p \ 0.001) and groups B and C (p \ 0.001; Fig. 1). The
PRSC also showed a significant prognostic value when
separately analyzing the completely resected tumors
without distant metastases (p \ 0.001), the homogenous
group of patients with PLF treatment (p \ 0.001), the
heterogenous group with other platin-based treatment
(p \ 0.001), and the small group of patients who were
treated with RCTX (p = 0.023).
In a multivariate analysis including the factors PRSC,
tumor differentiation (grading), resection category, and the
presence or absence of distant metastases at the time of
surgery, the PRSC (p \ 0.001; hazard ratio [HR] 1.93;
95 % CI 1.44–2.60) and tumor grading (p = 0.006; HR
1.54; 95 % CI 1.31–2.09) were independent prognostic
factors. The PRSC was still an independent prognostic
factor when analyzing both cohorts separately (data not
shown).
Union for International Cancer Control/American Joint
Committee on Cancer (UICC/AJCC) Staging
There was a strong association between the UICC/AJCC
anatomic staging system and the PRSC (p = 0.001). All
patients with UICC/AJCC stages III and higher were in the
unfavorable PRSC group C. However, there were 16
patients in the PRSC group A who had a UICC/AJCC II
stage, and nine patients who would be classified as UICC
III or IV. On the other hand, 21 patients in the PRSC group
B were classified as UICC/AJCC stage I, and 77 patients
were classified into the prognostically unfavorable UICC/
AJCC stages III/IV (Table 2). UICC/AJCC staging was
prognostically relevant for stages 0, I, II, III, and IV
(p \ 0.001; see Fig. 2a) and also when probing for the
anatomic substages 0, IA, IB, IIA, IIB, IIIA, IIIB, IIIC, and
IV (see Fig. 2b). However, patients with anatomic stage IA
had an outcome similar to those with stage IIa, whereas
stage IB patients had the best clinical outcome, which was
even better than patients with complete tumor regression
and without lymph node metastases (ypT0N0). A multi-
variate analysis including the factors UICC/AJCC staging,
tumor regression, resection category, and tumor grading
(differentiation) showed tumor regression (p = 0.005; HR
1.34; 95 % CI 1.09–1.65), tumor grading (p = 0.003; HR
1.66; 95 % CI 1.18–2.33), and resection status (p = 0.017;
HR 1.58; 95 % CI 1.09–2.3) as independent prognostic
factors, in contrast to UICC/AJCC staging (p = 0.058; HR
1.08; 95 % CI 0.99–1.17).
Moreover, the comparison between the PRSC and the
UICC staging groups showed significant advantages for the
PRSC with higher hazard ratios and lower AIC and SBC
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values compared with the UICC staging groups. This was
also found when analyzing the subcohorts of the collective
and when comparing the UICC stages grouped to stages I,
II, III, and IV without subgroups (Table 3). Therefore, the
PRSC can be regarded as a more desirable model for
prognostication in this patient collection.
DISCUSSION
We demonstrated in two cohorts of neoadjuvantly-
treated patients with esophageal adenocarcinoma that an
easily applicable scoring system (PRSC), which includes
the factors UICC/AJCC ypT category, ypN category, and
the degree of histopathological tumor regression serves as a
simple but highly useful post-treatment and postoperative
classification system. The PRSC revealed an accurate
correlation with survival, thereby discriminating three
groups of patients with significantly different outcomes.
The proposed PRSC also had better performance regarding
the estimation of prognosis than the current UICC/AJCC
staging system in our collective.
The prognosis of patients with locally advanced esoph-
ageal adenocarcinoma has improved over the last decades
due to advances in surgical techniques, patient selection,
and staging methods,13,14 and due to the now widely per-
formed multimodal treatment with peri- or preoperative
CTX or chemoradiotherapy1–4,15. Complete or subtotal
tumor regression can be observed in up to 30 % of patients
after CTX, a finding that has a significant prognostic
impact. Another 20 % of patients show partial tumor
regression after neoadjuvant treatment1,3,11. The impact of
histopathologic tumor regression after neoadjuvant treat-
ment may even exceed the prognostic impact of the depth
of tumor invasion (i.e. ypT category)11,16,17. Classification
of tumor regression grade (TRG), which represents one
part of the PRSC, has been proven to be objective and
reproducible18,19. We used the TRG system according to
Becker, which is based on the estimation of the percentage
Stage 0
Stage I
Stage II
Stage III
Stage IV
Censored
AJCC/UICC stage
P < 0.001
1.0
0.8
0.6
0.4
0.2
Months after surgery
a
Estimated probability
of survival
600 12 24 36 48
ypT0ypN0
Stage IA
Stage IB
Stage IIA
Stage IIB
Stage IIIA
Stage IIIB
Stage IIIC
Stage IV
Censored
AJCC/UICC stage
P < 0.001
1.0
0.8
0.6
0.4
0.2
Months after surgery
b
Estimated probability
of survival
600 12 24 36 48
FIG. 2 UICC/AJCC anatomic staging:
a UICC/AJCC anatomic staging and 5-
year overall survival; b UICC/AJCC
anatomic staging with subgroups and 5-
year overall survival. UICC/AJCC
Union for International Cancer Control/
American Joint Committee on Cancer
TABLE 3 Comparison of various goodness-of-fit criteria and tests of
significance
PRSC UICC
(with subgroups)
UICC
(0, I, II, III, IV)
Total collective
p Value \0.0001 \0.0001 0.0065
HR (95 % CI) 2.2 (1.7–2.8) 1.15 (1.1–1.2) 1.1 08 (1.0–1.1)
AIC 1530.757 1553.758 1566.636
SBC 1533.787 1556.789 1569.667
Munich
p Value \0.0001 \0.0001 0.0015
HR (95 % CI) 2.48 (1.8–3.3) 1.2 (1.1–1.3) 1.1 (1.0–1.2)
AIC 1108.319 1123.707 1137.93
SBC 1111.081 1126.469 1140.692
Heidelberg
p Value 0.0154 0.5997 0.9291
HR (95 % CI) 1.7 (1.1–2.6) 1.03 (0.9–1.2) 1.0 (0.9–1.1)
AIC 260.691 266.61 266.881
SBC 262.275 268.194 268.464
PRSC histopathologic prognostic score, UICC Union for International
Cancer Control, HR hazard ratio, AIC Akaike Information Criterion,
SBC Schwarz Bayesian Information Criterion
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of residual tumor8,11,18,20. Other authors use similar per-
centage-based steps of residual tumor to define different
TRGs, and have also described the 50 % cutoff for residual
tumor as prognostically relevant21,22. These systems, as
well as the Mandard classification,23 which is based on the
estimation of the relation of fibrosis to vital tumor, could be
easily applied for the proposed PRSC since the relevant
categories can be used in parallel to our system. The sec-
ond important parameter, which heavily influences
patient’s outcome, is the presence of lymph node metas-
tases11,22,24. Although tumor differentiation was also an
independent prognostic factor in our study, and is also
implemented by the AJCC into the prognostic staging of
early stages of untreated tumors,25,26 we did not include
this factor in our PRSC. There may be considerable dif-
ferences between the determination of tumor grading in
preoperative biopsies and the corresponding resection
specimen27. Furthermore, in the context of a multimodal
setting, it has to be emphasized that the estimation of tumor
differentiation in CTX- or RCTX-treated tumors in post-
treatment specimens may not be representative of the
tumor due to the marked therapy-induced cytotoxic chan-
ges (e.g. regression, cytopathic effects and high-grade
cellular atypia8,28). Moreover, in single cases, preoperative
biopsy material may be scarce and only contain superficial,
highly altered cellular material that may be sufficient for a
malignant diagnosis but not for accurate estimation of
tumor differentiation. The recently updated UICC/AJCC
TNM system (TNM7)12 recognizes esophageal adenocar-
cinoma as a separate tumor entity in contrast to esophageal
squamous cell carcinoma. Several changes, compared with
the previous UICC/AJCC TNM classification (TNM6),29
resulted in additional prognostic information5,26,30–32.
Although advantages of the updated UICC/AJCC TNM
system could also be demonstrated for patients undergo-
ing neoadjuvant treatment,24,33 staging systems that have
been originally developed for untreated, primary resected
tumors may have limitations because they do not consider
regressive alterations of the tumors16. Regarding the
previous TNM6 UICC/AJCC staging system, several
publications have addressed this issue and have proposed
alternatives or modifications to the UICC/AJCC staging
system16,22,34. In our collectives, there were marked
limitations, particularly in the lower UICC/AJCC stages,
regarding the prognostic value of the proposed staging
categories. Stage IA patients had the best outcome,
whereas stages II–IV showed similar overall survival
curves. Moreover, no explicit staging is provided for
tumors that show a complete regression of the primary
site of the tumor and absence of lymph node metastases.
These ypT0ypN0 tumors had a slightly worse outcome
compared with stage IA tumors. By contrast, classifica-
tion of tumors that show complete regression of the
primary tumor but not of lymph node or distant metas-
tases, which was observed in ten cases, should result in a
classification of stage IIB or higher. Unfortunately, the
number of cases with this finding was too low to achieve
reliable knowledge concerning the biological significance
of vital metastases in cases with complete tumor regres-
sion of the primary tumor site. However, our results
clearly show the limitations of the UICC/AJCC staging
system to accurately discriminate prognostically relevant
groups in our large cohort of esophageal adenocarcinoma
patients.
CONCLUSIONS
The easily applicable PRSC revealed an accurate cor-
relation with survival and outperformed the current UICC
staging system. Because a similar score is also applicable
in gastric cancer,9 such prognostically relevant, post-
treatment and postoperative classification systems may be
considered for future clinical practice in tailoring the
treatment of patients with locally advanced adenocarcino-
mas of the upper gastrointestinal tract after neoadjuvant
treatment.
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